6/11
06:50 am
phvs
Pharvaris Announces Annual Meeting of Shareholders
Low
Report
Pharvaris Announces Annual Meeting of Shareholders
6/4
06:57 am
phvs
Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses [Yahoo! Finance]
Medium
Report
Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses [Yahoo! Finance]
6/4
06:50 am
phvs
Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses
Medium
Report
Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses
5/13
06:50 am
phvs
Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses
Low
Report
Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses
5/9
09:06 am
phvs
Pharvaris (NASDAQ: PHVS) had its price target lowered by analysts at Wedbush from $35.00 to $31.00. They now have an "outperform" rating on the stock.
Low
Report
Pharvaris (NASDAQ: PHVS) had its price target lowered by analysts at Wedbush from $35.00 to $31.00. They now have an "outperform" rating on the stock.
5/8
04:23 pm
phvs
Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Medium
Report
Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
5/8
04:10 pm
phvs
Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update
Medium
Report
Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update
4/22
02:11 pm
phvs
Pharvaris (NASDAQ: PHVS) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $34.00 price target on the stock.
Low
Report
Pharvaris (NASDAQ: PHVS) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $34.00 price target on the stock.
4/15
01:18 pm
phvs
Pharvaris (NASDAQ: PHVS) had its price target lowered by analysts at Morgan Stanley from $35.00 to $34.00. They now have an "overweight" rating on the stock.
Low
Report
Pharvaris (NASDAQ: PHVS) had its price target lowered by analysts at Morgan Stanley from $35.00 to $34.00. They now have an "overweight" rating on the stock.
4/12
08:14 am
phvs
Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]
Low
Report
Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans [Yahoo! Finance]
4/11
01:02 pm
phvs
Pharvaris (NASDAQ: PHVS) had its price target raised by analysts at JMP Securities from $49.00 to $50.00. They now have a "market outperform" rating on the stock.
Low
Report
Pharvaris (NASDAQ: PHVS) had its price target raised by analysts at JMP Securities from $49.00 to $50.00. They now have a "market outperform" rating on the stock.
4/11
10:22 am
phvs
Pharvaris (NASDAQ: PHVS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $35.00 price target on the stock.
Low
Report
Pharvaris (NASDAQ: PHVS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $35.00 price target on the stock.
4/10
04:17 pm
phvs
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer [Yahoo! Finance]
Low
Report
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer [Yahoo! Finance]
4/10
04:17 pm
phvs
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
Low
Report
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
4/10
04:10 pm
phvs
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Low
Report
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
4/10
04:08 pm
phvs
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
Low
Report
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
4/4
07:03 am
phvs
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference [Yahoo! Finance]
Low
Report
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference [Yahoo! Finance]
4/4
06:50 am
phvs
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
Low
Report
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
3/19
09:31 am
phvs
Pharvaris (NASDAQ: PHVS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $35.00 price target on the stock.
Medium
Report
Pharvaris (NASDAQ: PHVS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $35.00 price target on the stock.